335 related articles for article (PubMed ID: 28277923)
21. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy.
Kondo J; Inoue M
Cells; 2019 May; 8(5):. PubMed ID: 31108870
[TBL] [Abstract][Full Text] [Related]
22. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
Sachs N; de Ligt J; Kopper O; Gogola E; Bounova G; Weeber F; Balgobind AV; Wind K; Gracanin A; Begthel H; Korving J; van Boxtel R; Duarte AA; Lelieveld D; van Hoeck A; Ernst RF; Blokzijl F; Nijman IJ; Hoogstraat M; van de Ven M; Egan DA; Zinzalla V; Moll J; Boj SF; Voest EE; Wessels L; van Diest PJ; Rottenberg S; Vries RGJ; Cuppen E; Clevers H
Cell; 2018 Jan; 172(1-2):373-386.e10. PubMed ID: 29224780
[TBL] [Abstract][Full Text] [Related]
23. Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine.
Colella G; Fazioli F; Gallo M; De Chiara A; Apice G; Ruosi C; Cimmino A; de Nigris F
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29466296
[TBL] [Abstract][Full Text] [Related]
24. Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids.
Choi SY; Cho YH; Kim DS; Ji W; Choi CM; Lee JC; Rho JK; Jeong GS
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572899
[TBL] [Abstract][Full Text] [Related]
25. Importance of organoids for personalized medicine.
Perkhofer L; Frappart PO; Müller M; Kleger A
Per Med; 2018 Nov; 15(6):461-465. PubMed ID: 30418092
[TBL] [Abstract][Full Text] [Related]
26. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
Costales-Carrera A; Fernández-Barral A; Bustamante-Madrid P; Guerra L; Cantero R; Barbáchano A; Muñoz A
Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31752287
[TBL] [Abstract][Full Text] [Related]
27. Personalizing pancreatic cancer organoids with hPSCs.
Zhang HC; Kuo CJ
Nat Med; 2015 Nov; 21(11):1249-51. PubMed ID: 26540385
[No Abstract] [Full Text] [Related]
28. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics.
Fujino S; Ito A; Ohue M; Yasui M; Mizushima T; Doki Y; Mori M; Miyoshi N
Biochem Biophys Res Commun; 2019 May; 513(2):332-339. PubMed ID: 30955861
[TBL] [Abstract][Full Text] [Related]
29. Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer.
Singh T; Neal AS; Moatamed NA; Memarzadeh S
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396714
[TBL] [Abstract][Full Text] [Related]
30. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs.
Santo VE; Rebelo SP; Estrada MF; Alves PM; Boghaert E; Brito C
Biotechnol J; 2017 Jan; 12(1):. PubMed ID: 27966285
[TBL] [Abstract][Full Text] [Related]
31. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
[TBL] [Abstract][Full Text] [Related]
32. Personalized
Pauli C; Hopkins BD; Prandi D; Shaw R; Fedrizzi T; Sboner A; Sailer V; Augello M; Puca L; Rosati R; McNary TJ; Churakova Y; Cheung C; Triscott J; Pisapia D; Rao R; Mosquera JM; Robinson B; Faltas BM; Emerling BE; Gadi VK; Bernard B; Elemento O; Beltran H; Demichelis F; Kemp CJ; Grandori C; Cantley LC; Rubin MA
Cancer Discov; 2017 May; 7(5):462-477. PubMed ID: 28331002
[TBL] [Abstract][Full Text] [Related]
33. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
Burkhart RA; Baker LA; Tiriac H
Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
[TBL] [Abstract][Full Text] [Related]
34. Emerging organoid models: leaping forward in cancer research.
Fan H; Demirci U; Chen P
J Hematol Oncol; 2019 Dec; 12(1):142. PubMed ID: 31884964
[TBL] [Abstract][Full Text] [Related]
35. What role could organoids play in the personalization of cancer treatment?
Francies HE; Garnett MJ
Pharmacogenomics; 2015; 16(14):1523-6. PubMed ID: 26485224
[TBL] [Abstract][Full Text] [Related]
36. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
37. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Xie BY; Wu AW
Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
[TBL] [Abstract][Full Text] [Related]
38. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.
Morgan MM; Johnson BP; Livingston MK; Schuler LA; Alarid ET; Sung KE; Beebe DJ
Pharmacol Ther; 2016 Sep; 165():79-92. PubMed ID: 27218886
[TBL] [Abstract][Full Text] [Related]
39. Organoids: An intermediate modeling platform in precision oncology.
Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
[TBL] [Abstract][Full Text] [Related]
40. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
